Denali Therapeutics Inc. (DNLI) shareholders
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.74−0.15 (-0.79%)
Close on Nov 13, 2026Market cap $3.00BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
97.7%
156M of 160M shares
Institutional holders
293
56 new, 28 sold out
Net institutional buying
8M
In Q2 2026
Insider trades, 12 months
0 buys · 7 sales
Net sold $1.30M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16,178,963 | 10.20% | 13G (passive) amendment | Jun 30, 2026 |
| Baillie Gifford & Co | 11,960,230 | 7.50% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 10,490,610 | 7.20% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DNLI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 16,178,963 | 10.12% | $416.12M | +7,659,771 | 0.27% |
| BlackRock, Inc. | 14,026,413 | 8.77% | $360.76M | +991,979 | 0.01% |
| Baillie Gifford & Co | 11,960,230 | 7.48% | $307.62M | −106,249 | 0.28% |
| State Street Corp | 7,049,304 | 4.41% | $181.31M | +777,303 | 0.01% |
| Temasek Holdings (Private) Ltd | 7,012,974 | 4.39% | $180.37M | – | 0.48% |
| Vanguard Portfolio Management LLC | 6,477,057 | 4.05% | $166.59M | +356,897 | 0.01% |
| Vanguard Capital Management LLC | 6,275,729 | 3.93% | $161.41M | +127,772 | 0.00% |
| FMR LLC | 4,535,836 | 2.84% | $116.66M | −39,538 | 0.01% |
| Goldman Sachs Group Inc | 4,155,895 | 2.60% | $106.89M | −251,360 | 0.01% |
| Geode Capital Management, LLC | 3,973,342 | 2.49% | $102.21M | +246,228 | 0.01% |
| Holocene Advisors, LP | 3,905,225 | 2.44% | $100.44M | +709,796 | 0.23% |
| Baker Bros. Advisors LP | 3,734,336 | 2.34% | $96.05M | +2,641 | 0.48% |
| UBS Asset Management Americas Inc | 3,161,972 | 1.98% | $81.33M | −1,270,342 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 3,136,149 | 1.96% | $80.66M | +672,003 | 0.01% |
| UBS Group AG | 3,120,592 | 1.95% | $80.26M | +549,248 | 0.01% |
| Alliancebernstein L.P. | 2,984,807 | 1.87% | $57.31M | +91,189 | 0.02% |
| Dimensional Fund Advisors LP | 2,860,604 | 1.79% | $73.58M | +168,429 | 0.01% |
| Norges Bank | 2,824,746 | 1.77% | $72.65M | New | 0.01% |
| Pictet Asset Management Holding SA | 2,791,206 | 1.75% | $71.89M | +232,341 | 0.07% |
| Capital Research Global Investors | 2,565,817 | 1.61% | $65.99M | +51,229 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 293 | 156M | 97.7% | 56 / 120 | 68 / 28 | 24M | 15M |
| Q1 2026 | 269 | 148M | 92.5% | 55 / 104 | 58 / 31 | 29M | 20M |
| Q4 2025 | 250 | 152M | 95.3% | 51 / 86 | 71 / 34 | 28M | 11M |
| Q3 2025 | 240 | 136M | 84.9% | 36 / 91 | 66 / 23 | 17M | 19M |
| Q2 2025 | 230 | 138M | 86.3% | 45 / 84 | 64 / 36 | 16M | 14M |
| Q1 2025 | 222 | 136M | 85.1% | 36 / 75 | 79 / 34 | 16M | 8M |
| Q4 2024 | 223 | 128M | 80.0% | 40 / 87 | 59 / 32 | 9M | 8M |
| Q3 2024 | 217 | 127M | 79.4% | 37 / 77 | 60 / 21 | 30M | 14M |
| Q2 2024 | 203 | 124M | 77.9% | 29 / 85 | 59 / 35 | 16M | 14M |
| Q1 2024 | 211 | 124M | 77.8% | 36 / 76 | 70 / 33 | 19M | 11M |
| Q4 2023 | 209 | 117M | 72.9% | 37 / 72 | 69 / 20 | 15M | 7M |
| Q3 2023 | 194 | 109M | 68.0% | 29 / 77 | 57 / 36 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
274 funds held DNLI in Q2 2026, 41% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DNLI | Value | % of fund | As of |
|---|---|---|---|---|---|
| T. Rowe Price Capital Appreciation Fund | 4,966,700 | 3.11% | $127.74M | 0.18% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,288,391 | 2.68% | $110.30M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,804,692 | 2.38% | $97.86M | 0.12% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,475,517 | 2.17% | $89.39M | 0.83% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,097,183 | 1.94% | $79.66M | 0.04% | Jun 30, 2026 |
| Vanguard U.S. Growth Fund | 3,037,857 | 1.90% | $63.92M | 0.13% | May 31, 2026 |
| SMALLCAP World Fund Inc | 2,496,890 | 1.56% | $64.22M | 0.07% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2,328,096 | 1.46% | $59.88M | 0.64% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,784,440 | 1.12% | $45.90M | 0.10% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,731,822 | 1.08% | $44.54M | 0.05% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,608,716 | 1.01% | $37.03M | 0.11% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 1,454,450 | 0.91% | $30.60M | 0.03% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 1,302,420 | 0.81% | $33.50M | 0.23% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 1,274,515 | 0.80% | $32.78M | 0.65% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 1,251,030 | 0.78% | $32.18M | 0.30% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Ryan J. Watts | President and CEO, Director | 2,417,217 | 1.51% | Aug 14, 2026 |
| Peter Scott Chin | Chief Medical Officer | 204,538 | 0.13% | Sep 9, 2026 |
| Alexander O. Schuth | COFO and Secretary | 802,744 | 0.50% | Sep 3, 2026 |
| Carole Ho | Chief Medical Officer | 241,585 | 0.15% | Aug 14, 2025 |
| Nancy Thornberry | Director | 19,686 | 0.01% | Sep 4, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | – | – | Jun 5, 2026 |
| Steve E. Krognes | Director | 819,999 | 0.51% | Jun 5, 2026 |
| Jennifer E. Cook | Director | 32,483 | 0.02% | Jun 5, 2026 |
| Jay T. Flatley | Director | 358,941 | 0.22% | Jun 5, 2026 |
| Peter S. Klein | Director | 33,941 | 0.02% | Jun 5, 2026 |
| Hauwermeiren Timothy Van | Director | 17,040 | 0.01% | Jun 5, 2026 |
| Bros. Advisors Lp Baker | Director | 3,415,958 | 2.14% | Jun 5, 2026 |
| Julian Baker | Director | – | – | Jun 5, 2026 |
| Felix Baker | Director | – | – | Jun 5, 2026 |
| Brothers Life Sciences LP Baker | Director | 3,422,366 | 2.14% | Jun 5, 2026 |
| David P. Schenkein | Director | 47,897 | 0.03% | Jun 5, 2026 |
| 667, L.P. | Director | – | – | Jun 5, 2026 |
| Marc Tessier-Lavigne | Director | 2,123,445 | 1.33% | Jun 5, 2025 |
| Vicki L. Sato | Director | 107,976 | 0.07% | Jan 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter Scott Chin Chief Medical Officer | Sep 4, 2026 | Sale | −1,654 | $22.29 | $36.87K | 204,538 |
| Nancy Thornberry Director | Sep 2, 2026 | Sale(10b5-1 plan) | −615 | $23.74 | $14.60K | 19,686 |
| Nancy Thornberry Director | Sep 2, 2026 | Sale(10b5-1 plan) | −10,824 | $22.85 | $247.33K | 20,301 |
| Alexander O. Schuth COFO and Secretary | Sep 1, 2026 | Sale(10b5-1 plan) | −2,768 | $23.44 | $64.88K | 278,995 |
| Ryan J. Watts President and CEO, Director | Aug 12, 2026 | Gift | −32,220 | – | – | 2,120,384 |
| Alexander O. Schuth COFO and Secretary | Aug 11, 2026 | Sale | −2,857 | $25.07 | $71.62K | 281,763 |
| Hauwermeiren Timothy Van Director | Jun 3, 2026 | Award | +6,408 | – | – | 17,040 |
| Jennifer E. Cook Director | Jun 3, 2026 | Award | +6,408 | – | – | 32,483 |
| Nancy Thornberry Director | Jun 3, 2026 | Award | +6,408 | – | – | 31,125 |
| Brothers Life Sciences LP Baker Director | Jun 3, 2026 | Award | +6,408 | – | – | 3,422,366 |
| Brothers Life Sciences LP Baker Director | Jun 3, 2026 | Award | +6,408 | – | – | 343,275 |
| David P. Schenkein Director | Jun 3, 2026 | Award | +6,408 | – | – | 21,665 |
| Jay T. Flatley Director | Jun 3, 2026 | Award | +6,408 | – | – | 22,628 |
| Steve E. Krognes Director | Jun 3, 2026 | Award | +6,408 | – | – | 38,202 |
| Peter S. Klein Director | Jun 3, 2026 | Award | +6,408 | – | – | 33,941 |
| Alexander O. Schuth COFO and Secretary | Jan 6, 2026 | Sale | −17,218 | $16.50 | $284.10K | 282,828 |
| Ryan J. Watts President and CEO, Director | Jan 6, 2026 | Sale | −35,198 | $16.50 | $580.77K | 296,833 |
| Ryan J. Watts President and CEO, Director | Jan 3, 2026 | Award | +78,960 | – | – | 332,031 |
| Alexander O. Schuth COFO and Secretary | Jan 3, 2026 | Award | +57,700 | – | – | 300,046 |
| Hauwermeiren Timothy Van Director | Nov 4, 2025 | Award | +10,632 | – | – | 10,632 |
| Ryan J. Watts President and CEO, Director | Sep 3, 2025 | Gift | −50,000 | – | – | 2,152,604 |
| Carole Ho Chief Medical Officer | Aug 13, 2025 | Sale(10b5-1 plan) | −806 | $14.64 | $11.80K | 216,585 |
| Carole Ho Chief Medical Officer | Aug 12, 2025 | Sale(10b5-1 plan) | −2,937 | $13.58 | $39.88K | 217,391 |
| Alexander O. Schuth COFO and Secretary | Aug 12, 2025 | Sale | −2,937 | $13.58 | $39.88K | 242,346 |
| Carole Ho Chief Medical Officer | Aug 5, 2025 | Option exercise | +44,655 | $0.68 | $30.37K | 220,328 |
| Ryan J. Watts President and CEO, Director | Jul 9, 2025 | Option exercise | +455,282 | $0.68 | $309.59K | 708,353 |
| Ryan J. Watts President and CEO, Director | Jul 9, 2025 | Sale(10b5-1 plan) | −495,282 | $15.00 | $7.43M | 253,071 |
| Ryan J. Watts President and CEO, Director | Jul 9, 2025 | Option exercise | +40,000 | $5.28 | $211.20K | 748,353 |
| Steve E. Krognes Director | Jun 3, 2025 | Award | +6,037 | – | – | 31,794 |
| Marc Tessier-Lavigne Director | Jun 3, 2025 | Award | +6,037 | – | – | 1,886,576 |
| Nancy Thornberry Director | Jun 3, 2025 | Award | +6,037 | – | – | 24,717 |
| Peter S. Klein Director | Jun 3, 2025 | Award | +6,037 | – | – | 27,533 |
| Jay T. Flatley Director | Jun 3, 2025 | Award | +6,037 | – | – | 16,220 |
| David P. Schenkein Director | Jun 3, 2025 | Award | +6,037 | – | – | 15,257 |
| Jennifer E. Cook Director | Jun 3, 2025 | Award | +6,037 | – | – | 26,075 |
| Bros. Advisors Lp Baker Director | Jun 3, 2025 | Award | +10,565 | – | – | 3,415,958 |
| Bros. Advisors Lp Baker Director | Jun 3, 2025 | Award | +10,565 | – | – | 336,867 |
| Carole Ho Chief Medical Officer | Jan 7, 2025 | Sale | −2,907 | $20.81 | $60.49K | 175,673 |
| Steve E. Krognes Director | Jan 7, 2025 | Sale | −3,339 | $20.81 | $69.48K | 25,757 |
| Alexander O. Schuth COFO and Secretary | Jan 7, 2025 | Sale | −2,907 | $20.81 | $60.49K | 244,308 |
| Ryan J. Watts President and CEO, Director | Jan 7, 2025 | Sale | −7,650 | $20.81 | $159.20K | 253,071 |
| Carole Ho Chief Medical Officer | Jan 6, 2025 | Sale | −12,255 | $20.22 | $247.80K | 178,580 |
| Alexander O. Schuth COFO and Secretary | Jan 6, 2025 | Sale | −12,255 | $20.22 | $247.80K | 247,215 |
| Ryan J. Watts President and CEO, Director | Jan 6, 2025 | Sale | −29,266 | $20.22 | $591.76K | 260,721 |
| Alexander O. Schuth COFO and Secretary | Jan 3, 2025 | Award | +54,180 | – | – | 259,470 |
| Carole Ho Chief Medical Officer | Jan 3, 2025 | Award | +54,180 | – | – | 190,835 |
| Ryan J. Watts President and CEO, Director | Jan 3, 2025 | Award | +54,180 | – | – | 289,987 |
| Vicki L. Sato Director | Jan 2, 2025 | Sale(10b5-1 plan) | −3,080 | $20.91 | $64.40K | 107,976 |
| Steve E. Krognes Director | Dec 31, 2024 | Sale(10b5-1 plan) | −30,000 | $20.25 | $607.50K | 29,096 |
| Alexander O. Schuth COFO and Secretary | Dec 27, 2024 | Option exercise | +6,708 | $5.28 | $35.42K | 205,290 |
| Carole Ho Chief Medical Officer | Nov 25, 2024 | Option exercise | +17,845 | $0.68 | $12.13K | 136,655 |
| Alexander O. Schuth COFO and Secretary | Nov 22, 2024 | Option exercise | +20,516 | $0.68 | $13.95K | 198,582 |
| David P. Schenkein Director | Nov 11, 2024 | Sale(10b5-1 plan) | −32,312 | $32.87 | $1.06M | 9,220 |
| David P. Schenkein Director | Nov 11, 2024 | Sale(10b5-1 plan) | −27,129 | $32.09 | $870.57K | 41,532 |
| David P. Schenkein Director | Nov 11, 2024 | Option exercise | +47,165 | $18.00 | $848.97K | 68,661 |
| Alexander O. Schuth COFO and Secretary | Nov 7, 2024 | Option exercise | +15,558 | $5.28 | $82.15K | 193,624 |
| Alexander O. Schuth COFO and Secretary | Nov 7, 2024 | Sale(10b5-1 plan) | −300 | $31.29 | $9.39K | 178,066 |
| Alexander O. Schuth COFO and Secretary | Nov 7, 2024 | Sale(10b5-1 plan) | −2,925 | $30.72 | $89.86K | 178,366 |
| Alexander O. Schuth COFO and Secretary | Nov 7, 2024 | Sale(10b5-1 plan) | −12,333 | $29.68 | $366.04K | 181,291 |
| Vicki L. Sato Director | Nov 7, 2024 | Sale(10b5-1 plan) | −1,020 | $30.00 | $30.60K | 111,056 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
9.85%
15M shares short
Days to cover
9.9
At 1M shares a day
Change since last report
-5.0%
From 15M shares
Short volume, 20 days
42.2%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Denali Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 39,910 shares on Sep 10, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Peter Scott Chin Officer | Sep 4, 2026 | 1,654 | $36.87K | Sep 4, 2026 | Restricted Stock Lapse - See Remarks |
| Nancy Thornberry Director | Sep 2, 2026 | 11,439 | $266.13K | Sep 2, 2026 | Restricted Stock Units |
| Alexander O. Schuth Officer | Sep 1, 2026 | 2,768 | $65.77K | Sep 1, 2026 | Restricted Stock Units |
| Alexander O. Schuth Officer | Aug 11, 2026 | 2,857 | $71.62K | Aug 11, 2026 | Restricted Stock Lapse - See Remarks |
| Carole Ho Former Affiliate | Feb 5, 2026 | 39,490 | $801.39K | Feb 5, 2026 | Exercise of options under a registered plan |
| Carole Ho Former Affiliate | Feb 4, 2026 | 150,000 | $3.18M | Feb 4, 2026 | Exercise of options under a registered plan |
| Carole Ho Former Affiliate | Feb 3, 2026 | 150,000 | $3.32M | Feb 3, 2026 | Exercise of options under a registered plan |
| Ryan J. Watts Director, Officer | Jan 6, 2026 | 35,198 | $580.77K | Jan 6, 2026 | Restricted Stock Lapse - See Remarks |
| Alexander O. Schuth Officer | Jan 6, 2026 | 17,218 | $284.10K | Jan 6, 2026 | Restricted Stock Lapse - See Remarks |
| Carole Ho Consultant | Jan 6, 2026 | 17,218 | $284.10K | Jan 6, 2026 | Restricted Stock Lapse - See Remarks |
| Carole Ho Officer | Dec 4, 2025 | 1,882 | $35.76K | Dec 4, 2025 | Restricted Stock Units |
| Carole Ho Officer | Aug 13, 2025 | 806 | $10.66K | Aug 13, 2025 | Restricted Stock Units |
| Alexander O. Schuth Officer | Aug 12, 2025 | 2,937 | $39.88K | Aug 12, 2025 | Restricted Stock Lapse - See Remarks |
| Carole Ho Officer | Aug 12, 2025 | 2,937 | $39.88K | Aug 12, 2025 | Restricted Stock Lapse - See Remarks |
| Ryan J. Watts Officer | Jul 9, 2025 | 495,282 | $7.10M | Jul 9, 2025 | Stock Options Exercise |
See a number that looks wrong?